NCT04601831View on ClinicalTrials.gov

'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 23, 2020

Primary Completion Date

August 6, 2024

Study Completion Date

May 27, 2025

Conditions
Non-Hodgkin Lymphoma
Interventions
RADIATION

Focal radiation therapy (RT)

"Radiation therapy for phase II:~Definitive 40-50 Gy EQD2 (i.e. 30 Gy in 5 fractions)~Hypofractionated regimen (i.e. 5 fractions in 1-2 weeks) recommended, but other fractionation schemes (10-20 fractions in 2-4 weeks) allowed."

Trial Locations (1)

75390

UT Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT04601831 - 'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL | Biotech Hunter | Biotech Hunter